合肥颀中科技股份有限公司 关于部分募集资金专户销户完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688352 证券简称：颀中科技 公告编号：2025-034 合肥颀中科技股份有限公司（以下简称"公司"）于上海证券交易所科创板 首次公开发行股票募集资金按照相关法律、法规及规范性文件的规定在银行开立 了募集资金专用账户。近日，公司已办理完成对部分募集资金专用账户的注销手 续，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2023 年 2 月 复》 （证监许可〔2023〕415 号） ，公司获准向社会公开发行人民币普通股（A 股） 募集资金净额为人民币 223,262.62 万元。上述募集资金到位情况已经天职国际会 计师事务所（特殊普通合伙）（以下简称"天职国际"）审验，并于 2023 年 4 月 （天职业字202327694 号）。 公司依照规定对募集资金进行了专户存储，并与中信建投证券股份有限公司、存 放募集资金的商业银行签订了《募集资金专户存储三方监管 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688352 证券简称：颀中科技 公告编号：2025-034 合肥颀中科技股份有限公司 关于部分募集资金专户销户完成的公告 合肥颀中科技股份有限公司（以下简称"公司"）于上海证券交易所科创板 首次公开发行股票募集资金按照相关法律、法规及规范性文件的规定在银行开立 了募集资金专用账户。近日，公司已办理完成对部分募集资金专用账户的注销手 续，具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2023 年 2 月 27 日出具的《关于同意合肥颀中科技股份有限公司首次公开发行股票注册的批 复》（证监许可〔2023〕415 号），公司获准向社会公开发行人民币普通股（A 股） 20,000.00 万股，每股发行价格为人民币 12.10 元，募集资金总额为人民币 242,000.00 万元，扣除发行费用人民币 18,737.38 万元（不含增值税）后，实际 募集资金净额为人民币 223,262.62 万元。上述募集资金到位情况已经天职国 ...

Summary of Key Points Core Viewpoint - The company, Hefei Qizhong Technology Co., Ltd., has announced a share repurchase plan to enhance shareholder value and implement an employee stock ownership plan, with a total expected repurchase amount between 75 million and 150 million RMB [1]. Group 1: Share Repurchase Plan - The share repurchase plan was first disclosed on June 19, 2025, and will be implemented from June 18, 2025, to June 17, 2026 [1]. - The repurchase price will not exceed 16.61 RMB per share, and the total repurchase amount will be no less than 75 million RMB [1]. - The company has already repurchased 550,343 shares, which accounts for 0.05% of the total share capital of 1,189,037,288 shares [1]. Group 2: Progress of Share Repurchase - The highest repurchase price recorded was 11.27 RMB per share, while the lowest was 11.10 RMB per share, with a total expenditure of 6,174,000.68 RMB (excluding transaction fees) [1][2]. - The company will adhere to relevant laws and regulations during the repurchase process and will disclose information regarding the progress of the repurchase in a timely manner [2][3].

证券代码：688352 证券简称：颀中科技 公告编号：2025-033 合肥颀中科技股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 | 回购方案首次披露日 | 2025/6/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 月 2025 18 6 | 6 | 日~2026 | 年 | 17 | 日 | | 预计回购金额 | 7,500万元~15,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 550,343股 | | | | | | | 累计已回购股数占总股本比例 | 0.05% | | | | | | | 累计已回购金额 | 6,174,000.68元 | | | | | | | 实际回购价格区间 | 11.10元/股~11.27元/股 | | | | | | 一、回购股份的基本情况 ...

Group 1 - Multiple listed companies announced share repurchase plans or progress on June 17, coinciding with the one-year anniversary of the "Science and Technology Innovation Board Eight Articles" [1] - Eight companies from the Science and Technology Innovation Board, including Guoda Materials and Huahai Qingke, proposed share repurchases, indicating a commitment to enhancing quality and returns [1] - Guoda Materials' chairman proposed a repurchase of A-shares using 200 million to 400 million yuan in special loans and self-raised funds, aimed at employee stock ownership plans or convertible bonds [1] Group 2 - Midea Group announced its first share repurchase under a new plan, buying back 2.0781 million shares at a total cost of 150 million yuan, with a future plan to repurchase between 5 billion to 10 billion yuan [2] - Tencent Holdings repurchased 980,000 shares for 500 million HKD, with prices ranging from 507 to 514 HKD per share [2] - As of this year, listed companies have repurchased a total of 71.71 billion yuan, with nine companies, including Kweichow Moutai and Ningde Times, repurchasing over 1 billion yuan each [2]

证券代码：688352 证券简称：颀中科技 公告编号：2025-032 合肥颀中科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关法律法规规定，公司在回购期间应当在每个月的前 3 个 交易日内公告截至上月末的回购进展情况，现将公司回购股份的进展情况公告如 下： 截至 2025 年 6 月 30 日，公司暂未实施股份回购。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实 ...

证券代码：688352 证券简称：颀中科技 公告编号：2025-031 ● 回购股份金额：不低于人民币 7,500 万元（含），不超过人民币 15,000 万元（含）； ● 回购股份资金来源：超募资金、自有资金及中信银行股份有限公司合肥分行（以 下简称"中信银行"）提供的股票回购专项贷款； ● 相关风险提示： 存在回购方案无法顺利实施的风险； 使本次回购股份所需公司自有资金和专项贷款资金未能筹措到位，可能存在回购 方案无法实施或者部分实施的风险； 合肥颀中科技股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 合肥颀中科技股份有限公司（以下简称"公司"）拟通过集中竞价交易方式回购 部分公司已发行的人民币普通股（A 股）股票，回购方案具体如下： 外部客观情况等发生重大变化，或其他导致公司董事会决定终止本次回购方案的 事项发生，则存在本次回购方案无法顺利实施或根据规则变更或终止回购方案的 风险； 规规定的期限内实施上述用途，则存在启动未转让部分股份注销程 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688352 证券简称：颀中科技 公告编号：2025-031 合肥颀中科技股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 合肥颀中科技股份有限公司（以下简称"公司"）拟通过集中竞价交易方式回购 部分公司已发行的人民币普通股（A 股）股票，回购方案具体如下： ● 回购股份金额：不低于人民币 7,500 万元（含），不超过人民币 15,000 万元（含）； ● 回购股份资金来源：超募资金、自有资金及中信银行股份有限公司合肥分行（以 下简称"中信银行"）提供的股票回购专项贷款； ● 回购股份期限：自公司董事会审议通过本次回购方案之日起 12 个月内； ● 相关股东是否存在减持计划：截至本公告披露日，公司控股股东合肥颀中科技 控股有限公司，持股 5%以上的股东 Chipmore Holding Company Limited、合肥芯屏 产业投资基金（有限合伙）未来 3 个月、未来 6 个月内不存在减持公司股票计划； 公司回购提议人、董事、监事、 ...

Core Viewpoint - Company Qizhong Technology plans to raise up to 850 million yuan through convertible bonds to invest in two projects aimed at enhancing its advanced packaging and testing capabilities for integrated circuits [1][5]. Investment Projects - The total investment for the high-pin-count micro-sized bump packaging and testing project is approximately 41.95 million yuan, with the company planning to use 41.9 million yuan from the raised funds [3]. - The advanced power and flip-chip packaging technology renovation project at Qizhong Technology (Suzhou) has a total investment of about 43.17 million yuan, with 43.1 million yuan expected to be funded from the new issuance [3]. - The combined total investment for both projects is around 85.11 million yuan, with the company intending to utilize 85 million yuan from the fundraising [3]. Business Focus and Market Position - Over half of the raised funds will be allocated to enhance the packaging and testing capacity for non-display chips, which currently contribute less than 10% to the company's revenue in 2024 [5]. - Qizhong Technology is one of the few domestic firms capable of large-scale production of various bump manufacturing technologies and has maintained a leading position in advanced packaging technology [6]. - The company reported a projected revenue of nearly 2 billion yuan in 2024, with its display driver chip packaging business expected to sell 1.845 billion units, generating 1.758 billion yuan in revenue, ranking third globally in this sector [6]. Financial Performance and Stock Status - Since its IPO in April 2023, Qizhong Technology's stock has underperformed, trading below its initial offering price of 12.1 yuan per share, with a notable drop to around 8 yuan [9]. - The company has experienced a decline in net profit, reporting 313 million yuan in 2024, a decrease of 15.71% year-on-year, attributed to rising costs such as equipment depreciation and employee compensation [10]. - The company plans to repurchase shares at a price not exceeding 16.61 yuan per share, with a total repurchase amount between 75 million and 150 million yuan [9].